Concert Pharma (CNCE) Tops Q4 EPS by 17c

Note: EPS may not be comparable

Concert Pharma (NASDAQ: CNCE) reported Q4 EPS of ($0.26), $0.17 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49